Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Mirikizumab Citrate-Free vs Reference Formulation
NCT05644353Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of mirikizumab in ulcerative colitis (UC) and Crohn's disease (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration at 2040 hours, Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity at 2040 hours and 1 more. Started Dec 2022; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT05644353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05644353.